However, while these treatment strategies alleviated symptoms and induced and maintained remission in patients with IBD, several observational cohort studies have reported that patients receiving thiopurines, anti-TNF monotherapy, or a combination of both drugs were at risk of developing lymphoma (19–21). This evidence concerns the gene TNF and lymphoma.